Navigation Links
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Date:5/26/2009

Data Confirm Tapentadol Efficacy and Tolerability for Acute Pain Patients

RARITAN, N.J., May 26 /PRNewswire-USNewswire/ -- It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicines during and after surgery is a leading risk factor for experiencing these side effects. Nausea and vomiting are uncomfortable and bothersome and can have an impact on a patient's recovery.

According to a new Phase 3 clinical study published in the June 2009 issue of Current Medical Research and Opinion, and in an online version of the journal, tapentadol immediate release (IR) tablets provided patients with equivalent efficacy in pain relief following orthopedic surgery and significant reduction in nausea and/or vomiting compared to oxycodone IR.

Results from the new Phase 3 study of tapentadol IR tablets, a prescription oral analgesic approved by the U.S. Food and Drug Administration (FDA) in November 2008, showed that patients receiving 50-mg or 75-mg of the medication experienced significant relief of moderate to severe acute pain after a bunionectomy, one of the most common foot surgeries, compared with placebo. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), Raritan, NJ, and Grunenthal GmbH, Aachen, Germany, supported this study.

The overall difference in the intensity of pain experienced by patients recovering from bunionectomy was examined during the first 12, 24, 48 and 72 hours after initiating treatment with tapentadol IR. Both tapentadol IR treatment groups showed a statistically significant improvement in pain compared to patients who received placebo, during all of these time periods (P <0.001), achieving both the primary efficacy endpoint of the sum of pain intensity difference (SPID) at 48 hours and secondary efficacy endpoints (SPID(12),
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
5. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
11. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Use of Risk ... programs to delay generic market entry results in $5.4 ... new survey and analysis by economic consulting firm ... - http://photos.prnewswire.com/prnh/20140723/129680 Required by the ... and biologics, REMS programs are intended to improve drug ...
Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Inc ., a clinical-stage epigenetics oncology company, announced today ... with entinostat in combination and as a single agent ... San Antonio Breast Cancer Symposium ... phase 2 study of exemestane with and without entinostat ...
... MALVERN, Pa., Dec. 1, 2011 Auxilium Pharmaceuticals, Inc. ... today announced that the first patient has been dosed ... (collagenase clostridium histolyticum) for the treatment of idiopathic ... Shoulder syndrome. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 2Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 3Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 4Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 6
(Date:7/23/2014)... of research suggesting a safe and effective role ... cancer, with fewer detrimental side effects and improved ... study will be published in final format today ... Endocrinology . , Breast cancer is the most ... States. Approximately 70% of breast cancers are diagnosed ...
(Date:7/23/2014)... July 23, 2014 Rich Dad® Education, a ... of their charity yard sale to support Habit for Humanity ... 100% of the proceeds will be donated to Habitat for ... are being donated to the Habitat for Humanity ReStore thrift ... 33903. , One of the highlights of the yard ...
(Date:7/23/2014)... York (PRWEB) July 23, 2014 Thousands ... to move forward in a federal multidistrict litigation underway ... Liebhard LLP reports. According to an Order dated July ... hospital’s bid for payment of a $1,000 fee for ... implant. , Among other things, the Order noted ...
(Date:7/23/2014)... better treating the pernicious disorders of obesity and dementia ... American University,s Center for Behavioral Neuroscience. In the paper, ... aimed at areas of the brain responsible for memory ... could play a role in reducing certain dementias., "In ... measures often fall short. This is a new way ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2
... , ... Care of Serious Illness is the first book to provide a comprehensive look at the ... E. Meier, Stephen L. Isaacs, Robert Hughes (Editors) , ... New York, NY (Vocus) April 1, 2010 -- Palliative Care: Transforming ...
... they know how cytomegalovirus continues to re-infect people , THURSDAY, ... how a virus known as cytomegalovirus (CMV), which infects up ... re-infects people again and again even though their immune systems ... always make people ill, but certain people, such as newborns ...
... SNM and the Radiological Society of North America (RSNA) ... at the Natcher Conference Center of the National Institutes ... workshop will focus on general issues of standardization to ... and analysis of images in clinical trials. The second ...
... beat vitamin B for those with scent-robbing viral infection, ... Acupuncture may help people who lose their sense of ... a new study, 15 patients with post-viral olfactory dysfunction ... acupuncture. These patients were compared with PVOD patients treated ...
... new study of brain activity in depressed and anxious people ... modified for better or for worse by anxiety. ... Behavioral Neuroscience , looked at depression and two types of ... panic; and anxious apprehension, better known as worry. The ...
... ... Mac platforms , ... Richardson, TX (PRWEB) April 1, 2010 -- Damaka, a technology pioneer in Mobile ... Real-time 2-way Video, Application Sharing) Sweeping™ between laptops and mobile devices earlier in May ...
Cached Medicine News:Health News:Palliative Care: Transforming the Care of Serious Illness 2Health News:Palliative Care: Transforming the Care of Serious Illness 3Health News:Demystifying a Common, Persistent Virus 2Health News:FDA, SNM and RSNA host April 13-14 two-topic imaging workshop 2Health News:Depressed? Fearful? It might help to worry, too 2Health News:Damaka Delivers Advanced Sweeping&#8482; Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks 2
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
... The Shuttle Relay Suture Passer allows braided ... tissue repair procedures. It may be ... suture material and in conjunction with anchors ... anchor) Additionally, the Shuttle Relay can ...
... EMR Electronic Medical Record organizes communication ... and with outside practitioners. It also ... and other data that traditionally rely ... the patient chart. With Microsoft Outlook ...
Medicine Products: